{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:37:23Z","timestamp":1791067043761,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","sfnmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Fetal and Neonatal Medicine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.siny.2022.101331","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T10:38:22Z","timestamp":1649414302000},"page":"101331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Using real-world data in pediatric clinical trials: Lessons learned and future applications in studies of persistent pulmonary hypertension of the newborn"],"prefix":"10.1016","volume":"27","author":[{"given":"Thomas F.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schmelter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.siny.2022.101331_bib1","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/jama.2012.12883","article-title":"The need for rigorous evidence on medication use in preterm infants: is it time for a neonatal rule?","volume":"308","author":"Davis","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.siny.2022.101331_bib2","first-page":"1185","article-title":"Development of drug therapies for newborns and children: the scientific and regulatory imperatives","volume":"64","author":"Mulugeta","year":"2017","journal-title":"Pediatr Clin"},{"key":"10.1016\/j.siny.2022.101331_bib3","series-title":"General clinical pharmacology considerations for neonatal studies for drugs and biological products","year":"2019"},{"key":"10.1016\/j.siny.2022.101331_bib4","series-title":"March of dimes report card","author":"March of Dimes","year":"2019"},{"key":"10.1016\/j.siny.2022.101331_bib5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamapediatrics.2013.4604","article-title":"Newborns, one of the last therapeutic orphans to be adopted","volume":"168","author":"Stiers","year":"2014","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.siny.2022.101331_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016293","article-title":"Global shortage of neonatal and paediatric antibiotic trials: rapid review","volume":"7","author":"Thompson","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.siny.2022.101331_bib7","unstructured":"Inomax, U.S. Prescribing Information, https:\/\/www.inomax.com\/wp-content\/themes\/inomax-website\/dist\/downloads\/Inomax-PI.pdf Accessed:."},{"key":"10.1016\/j.siny.2022.101331_bib8","unstructured":"Clinical Trials. Gov, PPHN neonates, https:\/\/clinicaltrials.gov\/ct2\/results?cond=PPHN&term=neonates+vasodilator&cntry=&state=&city=&dist= Accessed: 25 February 2022."},{"key":"10.1016\/j.siny.2022.101331_bib9","series-title":"HR 34, 114th congress, enacted on dec 13","article-title":"21st Century Cures Act","author":"Us Congress","year":"2016"},{"key":"10.1016\/j.siny.2022.101331_bib10","series-title":"Submitting documents using real-world data and real-world evidence to FDA for drugs and biologics","year":"2019"},{"key":"10.1016\/j.siny.2022.101331_bib11","unstructured":"U.S. Food and Drug Administration, Consideration on use of RWD and RWE, https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug 2021 Accessed: 25 February 2022."},{"key":"10.1016\/j.siny.2022.101331_bib12","unstructured":"European Medicines Agency, Use of Real World Evidence, https:\/\/www.ema.europa.eu\/en\/news\/vision-use-real-world-evidence-eu-medicines-regulation Accessed: 25 February 2022."},{"key":"10.1016\/j.siny.2022.101331_bib13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cpt.2461","article-title":"Marketing authorization applications made to the European Medicines agency in 2018-2019: what was the contribution of real-world evidence?","volume":"111","author":"Flynn","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.siny.2022.101331_bib14","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/archdischild-2019-317399","article-title":"Development of a neonatal adverse event severity scale through a Delphi consensus approach","volume":"104","author":"Salaets","year":"2019","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.siny.2022.101331_bib15","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.clinbiochem.2009.06.025","article-title":"Clinical laboratory reference intervals in pediatrics: the CALIPER initiative","volume":"42","author":"Jung","year":"2009","journal-title":"Clin Biochem"},{"key":"10.1016\/j.siny.2022.101331_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.semperi.2008.10.010","article-title":"The CBC: reference ranges for neonates","volume":"33","author":"Christensen","year":"2009","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.siny.2022.101331_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/jp.2015.140","article-title":"Reference intervals for reticulocyte parameters of infants during their first 90 days after birth","volume":"36","author":"Christensen","year":"2016","journal-title":"J Perinatol"},{"key":"10.1016\/j.siny.2022.101331_bib18","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/j.2040-4603.2021.tb00176.x","article-title":"Pediatric pulmonary hypertension: definitions, mechanisms, diagnosis, and treatment","volume":"11","author":"Mukherjee","year":"2021","journal-title":"Compr Physiol"},{"key":"10.1016\/j.siny.2022.101331_bib19","unstructured":"IBM, IBM Explorys EHR database, https:\/\/www.ibm.com\/watson-health\/about\/explorys Accessed:."},{"key":"10.1016\/j.siny.2022.101331_bib20","unstructured":"Optum Clinformatics, Clinformatics Data Mart https:\/\/www.optum.com\/content\/dam\/optum\/resources\/productSheets\/Clinformatics_for_Data_Mart.pdf Accessed: 25 February 2022."},{"key":"10.1016\/j.siny.2022.101331_bib21","doi-asserted-by":"crossref","first-page":"21340","DOI":"10.1038\/s41598-020-77286-6","article-title":"Multiscale classification of heart failure phenotypes by unsupervised clustering of unstructured electronic medical record data","volume":"10","author":"Nagamine","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.siny.2022.101331_bib22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CLEP.S242097","article-title":"Synthetic and external controls in clinical trials - a primer for researchers","volume":"12","author":"Thorlund","year":"2020","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.siny.2022.101331_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ghir.2016.09.005","article-title":"IGF-I in the clinics: use in retinopathy of prematurity","volume":"30\u201331","author":"Hellstr\u00f6m","year":"2016","journal-title":"Growth Hormone IGF Res"},{"key":"10.1016\/j.siny.2022.101331_bib24","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstr\u00f6m","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.siny.2022.101331_bib25","first-page":"228","article-title":"Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options","volume":"6","author":"Mutlu","year":"2013","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.siny.2022.101331_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0129383","article-title":"A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity","volume":"10","author":"Pertl","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.siny.2022.101331_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity","volume":"53","author":"Salman","year":"2015","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.siny.2022.101331_bib28","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.siny.2022.101331_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1740774509356002","article-title":"Summarizing historical information on controls in clinical trials","volume":"7","author":"Neuenschwander","year":"2010","journal-title":"Clin Trials"},{"key":"10.1016\/j.siny.2022.101331_bib30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/pr.2016.201","article-title":"Bronchopulmonary dysplasia: new becomes old again","volume":"81","author":"Day","year":"2017","journal-title":"Pediatr Res"},{"key":"10.1016\/j.siny.2022.101331_bib31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/jamapediatrics.2016.4141","article-title":"Revisiting the definition of bronchopulmonary dysplasia: effect of changing panoply of respiratory support for preterm neonates","volume":"171","author":"Isayama","year":"2017","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.siny.2022.101331_bib32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12887-019-1610-8","article-title":"The discovery BPD (D-BPD) program: study protocol of a prospective translational multicenter collaborative study to investigate determinants of chronic lung disease in very low birth weight infants","volume":"19","author":"Ofman","year":"2019","journal-title":"BMC Pediatr"}],"container-title":["Seminars in Fetal and Neonatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1744165X22000099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1744165X22000099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:47:13Z","timestamp":1761677233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1744165X22000099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1744165X22000099"],"URL":"https:\/\/doi.org\/10.1016\/j.siny.2022.101331","relation":{},"ISSN":["1744-165X"],"issn-type":[{"value":"1744-165X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using real-world data in pediatric clinical trials: Lessons learned and future applications in studies of persistent pulmonary hypertension of the newborn","name":"articletitle","label":"Article Title"},{"value":"Seminars in Fetal and Neonatal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.siny.2022.101331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101331"}}